With ASCO approaching and some major market moving events, I just wanted to provide some perspective with earnings season almost over. – I get the impression that ASCO will be.
Today, the American Society for Clinical Oncology(ASCO) posted a link to the ASCO 2014 meeting planner[LINK]. The planner also includes all of the abstract titles at the meeting. ASCO 2014.
Corcept Therapeutics (CORT) is currently awaiting topline Phase III data for Korlym(mifepristone) in psychotic depression in the second quarter. Currently, Corcept projects Korlym will do net revenue between $24-$28 million.
Members of Chimera Research Group have successfully been trading Merck for the past few months, especially Joe Gantos(@GantosJ). Merck has been one of the strongest big pharmas over the past.
Pfizer (PFE) isn’t traditionally on my watchlist as a name to follow, however, this may be an exception. Palbocicib is likely the most exciting pipeline product in development at Pfizer.
Lately, it seems like there is a new biotech IPO being filed every other day. Today, we want to take a look at a recent IPO, Auspex Pharmaceuticals (ASPX). Auspex.
On Wednesday, Protalix (PLX) will present data from their phase I clinical trial of oral glucocerebrosidase (GCD), or Oral GCD (PRX-112), in patients with Gaucher disease. The presentation will be.
On the wildly speculative front, Prana Biotechnology (PRAN) is a developer of metal protein attenuating compounds(MPAC) for neurodegenerative disorders. Shares are up over 350% in the past year as the.
Immuno-oncology was one of the hottest themes of 2013 and its been almost entirely a big pharma story. We saw Bristol-Myers Squibb, Merck and Roche reveal more data and future.
Following additional information released at ASCO 2013 and their recent quarterly updated, we wanted to take a moment to talk about Tesaro (TSRO). Since their IPO, Tesaro’s stock is up.
We last wrote on Horizon Pharma (NASDAQ: HZNP) following their FDA approval of RAYOS, but seems not much has changed. However, the stock has risen roughly 60% year to date.
This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. The first series in our preview covered what to expect in.
This year’s annual meeting of the American Society of Hematology(ASH13) is highly anticipated for a number of reasons. Pharmacyclic’s Ibrutinib could be viewed as one of the several catalysts sparking.
This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. Orphan diseases has been a key element in the bull market.
This year’s annual meeting of the American Society of Hematology (ASH13) is highly anticipated for a number of reasons. With the general market for the healthcare/biotech sector at all-time highs.
Celldex Therapeutics (CLDX) has one of the most anticipated data releases amongst small biotech companies this fall. They are scheduled to present data from their Phase 1 dose-escalation trial of.
This weekend is the 15th annual World Conference on Lung Cancer, sponsored by tge International Assoc. for The Study Of Lung Cancer (IASLC). It takes place Sunday October 27th through Wednesday 30th.
In a previous post, Jason Chew provided some background and analysis on Biocryst (BCRX) BCX4161, an oral drug candidate for the treatment of hereditary angioedema (HAE). Biocryst’s stock is up.
On Tuesday, the market was rather confused on what to make of the PREVAIL news. To be clear, this wasn’t entirely the market’s fault: Medivation released a poorly worded press.